Sign in
Taking people in United StatesNo phase

Studying people at higher risk of cancer to find early warning signs

Collects samples and information from people at higher risk of developing cancer.

Key facts

Who runs it
Dana-Farber Cancer Institute
Where
Boston, United StatesSee the site
Trial code
Registry title
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Status
Recruiting
People taking part
5,000 people, planned
Started
25 Apr 2023
Expected to end
25 Mar 2031
Type of study
Observational, 4 groups
Treatments tested
  • Samples
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people at higher risk of cancer, such as people with inherited risk, cancer survivors, people with early changes in cells, and their family members or healthy people.

Sex
All sexes can join.
Disease stage
People with a higher risk of cancer or an early, precancer condition (for example Barrett's esophagus, ductal/lobular carcinoma in situ, or lung nodules found on screening CT). Family members or healthy people can also join.
Earlier treatment
Childhood or adult cancer survivors whose past cancer treatment raised their cancer risk can join. People who are in other clinical trials or are getting treatment for precancer conditions can also join.
Biomarker or test result
Carriers of gene changes that raise cancer risk can join, but a gene test is not required.

Main reasons for not taking part

  • The record lists no exclusion criteria.

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type):; 1-Hereditary risk for cancer including; Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes; Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing); Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia); Hereditary Cancer Prediction Model-based elevated cancer risk; Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\&N cancer for example), etc
  • Exposed High Risk including; Childhood cancer survivors with treatment exposures associated with increased risk of cancer; Adult cancer survivors with treatment exposures associated with increased risk of cancer; Documented high level exposure to group 1 IARC carcinogens; Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age >50, Smoking history of >15 pack years, First-degree relative history of lung cancer or COPD; alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis
  • Precursor Lesions including; Breast: ductal/lobular carcinoma in situ (CIS) and atypical hyperplasia; GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia/adenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis; GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia/carcinoma in situ,; Lung: Adenomatous hyperplasia; H\&N: high-risk oral precancerous diseases; Skin: Class II melanocytic lesions. Squamous dysplasia; Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas; Thoracic: Lung nodules detected on screening CT that prompt further follow-up; GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia; Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others
  • FAMILY MEMBERS or healthy individuals

Who cannot take part

  • Note: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study
  • There are no exclusion criteria for the study

Where in United States

  • Dana-Farber Cancer InstituteBoston, United StatesContact: Sapna Syngal, MDTaking people

About the trial

What the trial wants to find out

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.

Read full original descriptionShow less

* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

The 4 groups in the trial

  • HEREDITARY RISK

    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues

    Treatment: Samples

  • EXPOSED HIGH RISK

    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues

    Treatment: Samples

  • PRECURSOR LESIONS

    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: * Blood * Buccal swab (saliva) or mouthwash * Urine * Stool * Biopsy or surgical tissue (i.e., bone marrow) * Bodily fluids * Other tissues

    Treatment: Samples

  • FAMILY MEMBERS

    These family members will be identified by the patients participating in the study. Blood, buccal cells, or saliva or oral rinses will be collected in one of three ways from family members of patients (i) at the time of consent; (ii) via a mailed blood kit or saliva kit; or (iii) at a separate appointment scheduled by the consented participant

    Treatment: Samples

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer
Plain-language title
Studying people at higher risk of cancer to find early warning signsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 August 2026